How to deal with biofilm – new approaches in periodontitis, mucositis and peri-implantitis
Non-surgical therapy remains the cornerstone of periodontal treatment. Patient compliance and proper selection and application of adjunctive antimicrobial agents for sustained biofilm control are important elements in achieving successful long-term results in the non-surgical periodontal therapy.
Non-surgical therapy remains the cornerstone of periodontal treatment. Attention to detail, patient compliance and proper selection and application of adjunctive antimicrobial agents for sustained biofilm control are important elements in achieving successful long-term results. Frequent re-evaluation and careful monitoring allows the practitioner the opportunity to intervene early in the disease state, to reverse or arrest the progression of periodontal and peri-implant diseases, with meticulous non-surgical anti-infective therapy. Various treatment modalities, including, antimicrobial therapy, gingival irrigations, and host modulation, may be used as adjunctive treatments in the non-surgical management of periodontal infections.
The emerging topic to be addressed in this dental webinar will be peri-implantitis. The non-surgical treatment of this condition has proven quite successful in the case of mucositis. Vice versa, in the case of progressive and irreversible bone loss, the non-surgical solution is not predictable, however, it is recommended as a first therapeutic phase. In some well documented clinical cases, the non-surgical option may have very satisfactory long- term outcomes. In other cases, it can help to significantly prolonging the survival rate of severely compromised implants. The protocol, particularly composite and differentiated, associated with the use of PERISOLV, will be described with clinical images, drawings and videos.
Disclaimer 2018 1st of March: Please observe that Dr. Roncati had wrong information. An application for a FDA approval for Perisolv is not filed. Consequently is Perisolv not available in USA yet.